MedTrace Logo

STHLM3 - Prostate Cancer Diagnostic Trial

NCT03639649 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58818

Last updated 2018-08-21

No results posted yet for this study

Summary

STHLM3 is a paired diagnostic trial aiming to assess whether a panel of biomarkers for prostate cancer can substantially reduce the proportion of men referred to biopsy whilst maintaining sensitivity for aggressive prostate cancer

Conditions

Interventions

DIAGNOSTIC_TEST

STHLM3

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
69 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03639649 on ClinicalTrials.gov